Lexaria Bioscience Corp. - Common Stock — Cash Flow (NASDAQ:LEXX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -2.66 M-3.99 M-4.88 M-5.88 M-4.96 M-10.45 M -7.43 M Cash from investing activities -26.84 K193.88 K-180.64 K-169.61 K-188.6 K-243.02 K -243.98 K Cash from financing activities 2.7 M13.42 M-44.6 K1.59 M—6.05 M 6.52 M Free cash flow -2.66 M-3.99 M-4.88 M-5.88 M-4.96 M-10.45 M -7.45 M

News

Lexaria launches 2026 research program for drug delivery tech

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience closes $3.5 million registered direct offering

Lexaria Bioscience raises $3.5 million in at-market offering

Lexaria Bioscience stock plunges after $3.5M at-the-market offering

Lexaria Bioscience extends pharmaceutical evaluation agreement